Analysis of pazopanib (Viant) detailed instructions and medication precautions

1. Introduction to drugs
Pazopanib (trade name Votrient) is an oral small molecule multi-target tyrosine kinase inhibitor (TKI) mainly used to treat advanced renal clear cell carcinoma (RCC) and certain types of soft tissue sarcoma (STS). It blocks tumor angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR), thereby reducing tumor oxygen and nutrient supply, while directly inhibiting tumor cell proliferation. Pazopanib is an important member of targeted therapy drugs and provides a new treatment option for patients with advanced tumors.
2. Indications, usage and dosage
1.Indications
Adult patients with advanced clear cell renal cell carcinoma (RCC) who are treatment-naïve or who have failed previous treatments with other therapies.
Soft tissue sarcoma (STS) that is not suitable for surgical resection or radiation therapy.
2. Usage and dosage
Pazopanib is taken orally, once daily, 800 mg each time (standard adult dose). Take it on an empty stomach or within 2 hours after a meal. Swallow the tablet whole without chewing or crushing.
For patients with liver function impairment or poor tolerance, the dose can be gradually adjusted according to the doctor's recommendation, such as 400–600 mg per day.

Discontinuation of medication or adjustment of dosage should be done in accordance with the doctor's advice and avoid making changes on your own to prevent the efficacy from decreasing or side effects from worsening.

3. Precautions when taking medication

1. Diet and medication
Pazopanib is best taken on an empty stomach, but if stomach discomfort occurs, it can be taken 2 hours after a meal.
Avoid taking it with high-fat foods, as high-fat meals may affect drug absorption and lead to unstable blood drug concentrations.
Foods or drinks containing grapefruit juice that may affect liver CYP3A4 metabolism are prohibited to avoid increasing drug blood concentrations and increasing the risk of toxicity.
2. Common adverse reactions and management
Hypertension: Pazopanib can cause an increase in blood pressure. Blood pressure needs to be monitored regularly during use. If there is a significant increase, antihypertensive drugs should be used or the dose should be adjusted under the guidance of a doctor.
Abnormal liver function: It may lead to an increase in ALT, AST, and bilirubin. Liver function tests should be done before taking the drug and reviewed regularly during treatment. If severe liver damage occurs, the drug needs to be temporarily discontinued or the dose reduced.
Gastrointestinal reactions: including diarrhea, nausea, vomiting and oral ulcers, etc. It is recommended to eat a light diet, maintain adequate fluids, and use symptomatic drugs under the guidance of a doctor.
Skin reactions: rash on hands and feet, dry skin, etc. Use daily moisturizing and skin care products while avoiding severe friction.
3.Drug interactions
Pazopanib is mainly metabolized by CYP3A4. Avoid simultaneous use with strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) to avoid affecting the efficacy or increasing toxicity.
When used in combination with anticoagulants, antihypertensive drugs, etc., blood pressure, coagulation function, and liver and kidney indicators must be closely monitored to ensure safety.
4. Medication for special groups
Elderly patients: Due to decreased liver and kidney function, tolerance may be low. It is necessary to evaluate the overall health status before taking the drug and reduce the dose if necessary.
Pregnancy and lactation: Pazopanib is contraindicated in pregnant women and breastfeeding should be stopped during lactation to avoid the drug affecting the baby through milk.
Patients with impaired liver function: Patients with moderate to severe liver function impairment should use it with caution. If necessary, start with a low dose and monitor liver function indicators.
4. Medication monitoring and follow-up
1. Hematology examination: Regular blood tests are required before medication and during treatment, and attention should be paid to white blood cells, platelets and anemia.
2. Liver and kidney function monitoring: Review liver and kidney function every 2-4 weeks to detect drug-induced damage in a timely manner.
3. Cardiovascular monitoring: Long-term medication requires monitoring of blood pressure and electrocardiogram, especially for patients with previous hypertension or heart disease.
4. Imaging follow-up: According to the doctor's recommendations, CT or MRI examinations are performed regularly to evaluate tumor control and adjust treatment plans.
5. Suggestions on patient medication management
1. Strictly follow the doctor's instructions: take the medicine on time every day, and do not increase or decrease the dose or stop the medicine on your own.
2. Record adverse reactions: Provide detailed feedback on physical condition to the doctor during each follow-up visit so that dosage can be adjusted or side effects can be dealt with in a timely manner.
3. Lifestyle management: Maintaining a reasonable diet, moderate exercise and adequate rest to avoid infection and excessive mental stress will help improve efficacy and tolerance.
4. Cooperation of family members: For elderly patients or the frail, family members should assist in supervising medication taking and monitoring blood pressure, weight, mental status and other indicators.
Pazopanib, as a multi-target tyrosine kinase inhibitor, plays an important role in the treatment of advanced renal cancer and soft tissue sarcoma. Reasonable usage and dosage, regular daily medication and strict monitoring of liver and kidney function, blood pressure and blood indicators are the keys to ensuring efficacy and safety. While using pazopanib, patients should closely cooperate with their doctors, provide timely feedback on adverse reactions, and follow the principles of individualized treatment to obtain the best therapeutic effect.
Reference: https://www.drugs.com/